Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Ischemic Stroke l: Introduction

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of Fibrinogen on Tenecteplase Treatment in Acute Ischaemic Stroke After 4.5 Hours of Symptom Onset: A Post Hoc Analysis of the TRACE-III Trial.

Neurology and therapy·2026

Same author

Blood pressure management in patients receiving rescue stenting after failed endovascular treatment in large vessel occlusion acute ischaemic stroke: a multicentre registry.

European stroke journal·2026

Same author

2025 update to European Stroke Organisation (ESO) guideline on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage.

European stroke journal·2026

Same author

Intensive Versus Standard Systolic Blood Pressure Targets Following Successful Endovascular Thrombectomy for Acute Ischemic Stroke: A Systematic Review With Frequentist and Bayesian Meta-Analysis.

Stroke (Hoboken, N.J.)·2026

Same author

Automated perfusion imaging did not improve reliability of ASPECTS or collateral score in late-window large vessel occlusion stroke.

Journal of neurointerventional surgery·2026

Same author

ESO annual stroke evidence update 2025.

European stroke journal·2026

Search research articles

Related Experiment Video

Updated: May 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins and cerebral hemodynamics.

Sotirios Giannopoulos¹, Aristeidis H Katsanos, Georgios Tsivgoulis

¹Department of Neurology, Columbia University Medical Center, New York, NY, USA. sgiannop@uoi.gr

Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism

|August 30, 2012

Summary

Statins improve stroke outcomes by enhancing cerebral blood flow and autoregulation, primarily through nitric oxide pathways. Long-term use significantly boosts cerebral vasomotor reactivity in patients with cerebrovascular conditions.

Related Experiment Videos

Last Updated: May 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Neurology
Pharmacology
Cerebrovascular Medicine

Background:

HMG-CoA reductase inhibitors (statins) are linked to better stroke outcomes.
This effect may stem from improved cerebral hemodynamics and autoregulation via nitric oxide pathways.
While animal studies show enhanced blood flow post-stroke, clinical evidence is less conclusive.

Purpose of the Study:

To investigate the impact of statins on cerebral hemodynamics and autoregulation.
To determine if statin administration improves cerebral vasomotor reactivity in specific patient groups.

Main Methods:

Review of existing literature on statins, stroke outcomes, and cerebral autoregulation.
Analysis of clinical data regarding statin effects on cerebral blood flow and vasomotor reactivity.

Main Results:

Statins show a palliative effect on cerebral hemodynamics and autoregulation, partly via eNOS upregulation.
Clinical evidence for enhanced cerebral blood flow post-stroke is limited.
Long-term statin use significantly improves cerebral vasomotor reactivity in patients with severe small vessel disease, aneurysmal subarachnoid hemorrhage, or impaired baseline CA.

Conclusions:

Statins positively influence cerebral autoregulation and hemodynamics.
Long-term statin therapy is beneficial for improving cerebral vasomotor reactivity, particularly in at-risk patient populations.
Further clinical research is warranted to fully elucidate statin's role in stroke outcome improvement.